Rivastigmine
| Evidence Level: L5 | Predicted Indications: 1 |
Table of Contents
Rivastigmine: From Alzheimer Disease to Glaucoma
One-Sentence Summary
Rivastigmine is a cholinesterase inhibitor originally used to treat Alzheimer disease and related neurodegenerative conditions. The TxGNN model predicts it may be effective for glaucoma, but there are currently no registered clinical trials, and the support consists of 3 publications (1 animal study and 2 reviews).
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Alzheimer disease (the Canadian licence records list no approved indication text) |
| Predicted New Indication | Glaucoma |
| TxGNN Prediction Score | 0.9927 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs on record: at least 17; cancelled: 3) |
| Number of DINs | at least 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available from the compiled sources. Based on the known drug class, rivastigmine is a cholinesterase inhibitor that blocks the breakdown of acetylcholine by acetylcholinesterase and butyrylcholinesterase. Its use in Alzheimer disease rests on raising acetylcholine levels in the brain.
Glaucoma is a disease in which raised intraocular pressure (IOP) damages the optic nerve. In the eye, higher cholinergic tone can make the ciliary muscle contract and improve fluid outflow through the trabecular meshwork, which lowers IOP. This is the same principle behind established cholinergic agents such as pilocarpine, physostigmine and echothiophate. The mechanistic link is therefore inferred from drug class rather than from confirmed mechanism data.
The only direct experimental support is a 2000 study in which topical rivastigmine lowered IOP in normotensive rabbits. A 2024 review of cholinergic agents for IOP reduction gives further indirect support. The very high TxGNN score is a computational prediction and should not be treated as clinical evidence.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 10673128 | 2000 | Preclinical (rabbit) | J Ocul Pharmacol Ther | Topical rivastigmine, a selective carbamate-type acetylcholinesterase inhibitor, lowered IOP in normotensive rabbits |
| 39130374 | 2024 | Review | Front Mol Biosci | Reviews how cholinergic signalling in the anterior eye affects IOP; notes that approved M3 agonists are limited by systemic cholinergic side effects |
| 27967267 | 2017 | Review | Expert Opin Ther Pat | Patent review of acetylcholinesterase inhibitors and reactivators; mild AChE inhibition has therapeutic relevance in Alzheimer disease, myasthenia gravis and glaucoma |
Canada Market Information
The first five are shown below.
| DIN | Product Name |
|---|---|
| 02242118 | EXELON |
| 02401630 | MED-RIVASTIGMINE |
| 02242117 | EXELON |
| 02552280 | JAMP RIVASTIGMINE CAPSULES |
| 02401614 | MED-RIVASTIGMINE |
The full list also includes Exelon patch strengths (5, 15), Mylan, Sandoz, Apo and Jamp generics, covering both capsule and patch products.
Safety Considerations
- Contraindication-related conditions (from the knowledge graph, not label text): epilepsy, basal ganglia disease, focal hand dystonia, blepharospasm, chronic obstructive pulmonary disease, asthma (including intrinsic and allergic), diarrheal disease, sudden cardiac arrest, heart conduction disease, sick sinus syndrome, atrioventricular block, anorexia nervosa, active peptic ulcer disease, urinary tract obstruction, and parkinsonian disorders including Parkinson disease.
- Drug interactions: 100 interactions were found in total. The most important is bupropion (Major). Many others are rated Moderate, mainly:
- anticholinergics (atropine, hyoscyamine, glycopyrronium, dicyclomine, trospium, clidinium, mepenzolate);
- acid reducers (famotidine, ranitidine, cimetidine);
- antibiotics (clarithromycin, metronidazole, levofloxacin);
- antiemetics (dolasetron, palonosetron);
- others such as loperamide and bowel-preparation agents.
- Ocular-use considerations: A topical formulation would need to address systemic cholinergic effects, ocular irritation, and the possibility of myopia or cataract with chronic cholinesterase inhibitor exposure.
Package insert warnings and contraindications were not available in the compiled data. Please refer to the Health Canada package insert.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is biologically plausible and supported by one rabbit study, but there is no human data and no registered trials. The evidence level is L4, and the label-based safety review has not yet been possible.
To proceed, the following is needed:
- Obtain and review the Health Canada package insert for warnings and contraindications
- Retrieve mechanism of action data from DrugBank
- Confirm the available routes and a topical ophthalmic formulation (none is currently listed)
- Generate further preclinical data on efficacy and ocular tolerability, and compare with existing IOP-lowering agents
- Assess the safety implications of the knowledge-graph contraindications and the bupropion interaction in glaucoma patients
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.